Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis

Kamiya, Naoto; Suzuki, Hiroyoshi; Yano, Masashi; Endo, Takumi; Takano, Makoto; Komaru, Atsushi; Kawamura, Koji; Sekita, Nobuyuki; Igarashi, Takashi; Ichikawa, Tomohiko

doi:10.1016/j.urology.2009.11.049

Cited by 38 publications

(38 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Searching for effective and sensitive serum indicators is important, as prostate cancer patients may present bone pain or pathological fracture. Gleason score ≥ 8, PSA ≥ 20 mg/L, and ALP elevation are risk factors for prostate cancer bone metastases (Kamiya et al, 2010;Moslehi et al, 2013). Bone metastases destroy the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption .…”

Section: Discussionmentioning

confidence: 99%

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Wei¹,

Li²,

Yang³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Bone metastasis is a common complication in prostate cancer patients that can cause bone pain and pathological fracture. This study tested serum levels of prostate specific antigen (PSA), alkaline phosphatase (ALP), bone sialoprotein (BSP), collagen type I pyridine crosslinking peptide (ICTP) in prostate cancer patients and the significance of the receiver operator characteristic (ROC) curve in the diagnosis of prostate cancer bone metastases. Eighty-three prostate cancer patients were enrolled including 42 in the bone metastases group and 41 in the non-bone metastases group. Serum levels of BSP, ALP, ICTP, and PSA were highest in the bone metastases group followed by the non-bone metastases group, hyperplasia group, and then the control group (P < 0.05). Based on Gleason score, serum levels were highest in the poorly differentiated group followed by moderately differentiated and well-differentiated groups (P < 0.05). ROC curve analysis revealed that the diagnostic efficiency of the biomarkers in turn was BSP, PSA, ICTP, and ALP. The sensitivity of BSP, ALP, ICTP, and PSA in the diagnosis of prostate cancer bone metastases were 80.95, 57.14, 69.05, 71.43%, respectively, and the specificity of the same markers were 72. 80, 64.80, 76.80, and 88.80%, respectively. Combined detection of the four markers improved sensitivity to 97.62% and the negativepredictive value increased to 97.60%. PSA + BSP showed the best efficiency when combining two markers. In conclusion, serum levels of BSP, ALP, ICTP, and PSA increased in patients with bone metastases, and combined detection of all markers could improve the positivepredictive value.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Wei¹,

Li²,

Yang³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…A combination of tartrate-resistant acid phosphatase, alkaline phosphatase and PSA can obviate the need for a bone scan in 70% of cases [20]. In addition, Kamiya et al [21] reported that serum carboxyterminal pyridinoline cross-linked telopeptide parts of type-I collagen level was a more reliable marker than the others used to detect BM spread and to predict survival probability in PCa patients with BM. These serum markers are candidates to be incorporated to optimize our model in future studies.…”

Section: Discussionmentioning

confidence: 99%

Should Bone Scan be Performed in Chinese Prostate Cancer Patients at the Time of Diagnosis?

Wang

Guo²,

Xu³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Background: Prostate cancer (PCa) is increasingly being diagnosed in China. Early detection of bone metastases (BM) is critical in the management of patients with high-risk PCa. The aim of this study is to establish a screening model to determine if bone scan should be performed for BM in Chinese patients at the time when PCa is diagnosed. Materials and Methods: The study included 488 patients who were diagnosed with PCa between 2009 and 2011 at a single center. All patients received bone scans using technetium ^99mTc methylene diphosphonate at the initial staging. If the bone scan finding was equivocal, computed tomography or magnetic resonance imaging was performed to confirm the diagnosis. Age, prostate-specific antigen (PSA) at diagnosis, clinical stage assigned according to the TNM 2002 staging system and biopsy Gleason score were collected in all patients. Multivariate logistic regression analysis was performed to identify statistically significant covariates and then receiver operating characteristic (ROC) curves were generated to identify optimal cut-off values. Using these cut-off values, a formula was devised to calculate an index value for BM screening at diagnosis. The model was cross-validated using the leave-one-out method. Results: Of the 488 patients, 65 patients (13.3%) had BM. The area under the ROC curve was 0.87 (95% confidence interval 0.83-0.94). The sensitivity of the cut-off point was 87.7% and the speciﬁcity was 73.1%. Bone scan is needed for all cT4 PCa patients, however, it is also advisable for cT1-T3 PCa patients who have a biopsy Gleason score ≤3 + 4 and a PSA >132.1, and for cT1-T3 patients having a Gleason score of ≥4 + 3 and PSA >44.5. Conclusions: The regression model may help determine if bone scan is needed to detect BM from PCa at the time of diagnosis. The model was generated upon a single center experience. Further validation is needed in future studies.

show abstract

“…Numerous studies analyze the influence of bone metastases of different tumors on bone formation and resorption markers. Jung et al [10] and Kamiya et al [18] find significantly elevated concentrations of different bone formation and resorption markers in case of bone metastases. The results of Halleen et al [11], Lyubimova et al [13], Chao et al [14],and Yao et al [15] show promising findings regarding the bone resorption marker TRACP 5b in the question of bone metastases.…”

Section: Bone Trap Assaymentioning

confidence: 97%

“…One approach is the analysis of bone formation and resorption markers, generated in processes of the bone metabolism [10,11,16,18]. Numerous studies analyze the influence of bone metastases of different tumors on bone formation and resorption markers.…”

Section: Bone Trap Assaymentioning

confidence: 99%

Untitled

2014

Integr Cancer Sci Therap

View full text Add to dashboard Cite

The objective of this study was to assess the diagnostic value of the bone resorption marker tartrate-resistant acid phosphatase isoform5b (TRACP 5b) in detecting bone metastases in patients with renal cell carcinoma (RCC). Serum samples of 64 patients with histologically proven RCC were analyzed. Using bone scintigraphy, these patients were divided into 2 groups: 30 patients with RCC without bone metastases and 34 patients with RCC with bone metastases. TRACP 5b concentrations were analyzed in the serum using the Bone TRAP Assay. TRACP 5b concentrations were significantly elevated (p=0.014) in patients with bone metastases (median: 31.9 U/L) compared with patients without bone metastases (median: 8.7 U/L). Elevated TRACP 5b concentrations detected bone metastases with sensitivity of 76.5% and specificity of 36.7%. TRACP 5b appears to be an effective biomarker of bone metastases in patients with RCC.

show abstract

Implications of Serum Bone Turnover Markers in Prostate Cancer Patients With Bone Metastasis

Cited by 38 publications

References 29 publications

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases

Should Bone Scan be Performed in Chinese Prostate Cancer Patients at the Time of Diagnosis?

Untitled

Contact Info

Product

Resources

About